HBW Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

HBW Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-377	Closed	-$235K	–	227
2020 Q2	$235K	Sell	377 -59	-14%	-$33.5K	0.11%	157
2020 Q1	$213K	Sell	436 -118	-21%	-$48.7K	0.15%	96
2019 Q4	$208K	Buy	+554	New	+$186K	0.12%	132

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HBW Advisory Services's REGN Position: Q3 2020 in Review

HBW Advisory Services sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 377 shares — an estimated $235K sold.

HBW Advisory Services first reported a position in REGN in Q4 2019 and held it in 3 quarters. The position peaked at $235K in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

HBW Advisory Services reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
HBW Advisory Services sold 377 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $235K.
HBW Advisory Services first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 3 quarters.
HBW Advisory Services's Regeneron Pharmaceuticals position peaked at $235K in Q2 2020.
907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on HBW Advisory Services's 13F filing for Q3 2020, filed 14 Oct 2020.